JILIN AODONG(SZ:000623)2025-07-17 08:00Group 1: Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a total revenue of 2,273.76 million CNY in 2024, with traditional Chinese medicine contributing 1,605.54 million CNY (61.50%), chemical drugs 276.85 million CNY (10.61%), and retail and wholesale of chain pharmacies 391.37 million CNY (14.99%) [2][3] - The health sector achieved sales of 212.13 million CNY, accounting for 8.13% of total revenue [2][3] Group 2: Key Products and Market Performance - The main product, "Anshen Bnona Liquid," has a broad audience due to increasing insomnia cases, with significant consumer recognition of its efficacy and quality [3] - "Xuefu Zhuyu Oral Liquid," a classic formula, has gained market attention and was selected for centralized procurement, which is expected to enhance its sales scale and market share [4] Group 3: Investment and Financial Performance - As of March 31, 2025, the company holds 1,529,911,767 shares of GF Securities, representing 20.11% of its total share capital [6] - GF Securities reported a net profit of 9,636.83 million CNY in 2024, with the company's investment income from GF Securities reaching 1,749.40 million CNY, a 40.69% increase from the previous year [6] Group 4: Shareholder Returns - The company has implemented cash dividends for 17 consecutive years, totaling 4.505 billion CNY since its listing, and plans to enhance the stability and predictability of future dividends [6]